Regorafenib increases overall survival in hepatocellular carcinoma study
Results from the Phase III RESORCE trial investigatingBayer’s regorafenib in patients with unresectable hepatocellular carcinoma (HCC) who progressed during treatment with sorafenib (Nexavar) tablets have been announced.
Click on this link for more information.
